What You Should Know:
– Paradigm Health’s acquisition of Flatiron Health’s Clinical Research Business, coupled with a long-term strategic partnership, marks a structural shift in how oncology trials are conducted and how patients across the country gain access to them.
– The deal brings together the nation’s most extensive tech-enabled oncology research network with an AI-powered trial infrastructure, creating a unified ecosystem designed to expand trial capacity, reduce operational friction and deliver more representative evidence.
Paradigm Health and Flatiron Health: Reshaping the U.S. Clinical Research Landscape
Through this transaction, Paradigm Health’s network now spans more than 25 academic medical centers and health systems, nearly 100 community oncology practices and more than 2.4 million patients nationwide. This expanded footprint allows trials to meet patients where they already receive care rather than relying on a small number of high-volume research centers—a change that is particularly consequential for rural and underserved populations.
Flatiron’s established research tools—built around its OncoEMR network and community-practice relationships—will be natively integrated into Paradigm’s end-to-end platform. This alignment allows sponsors and sites to operate within a single, AI-enabled workflow that streamlines documentation, accelerates feasibility assessments, and lowers the infrastructure burden typically shouldered by clinical sites. Both organizations emphasize that the partnership is designed to create a smoother transition for health systems and community clinics, preserving existing research relationships while augmenting them with more sophisticated digital capabilities. The collaboration also strengthens Paradigm’s ability to support biopharma sponsors end-to-end, including running pragmatic Phase IV studies embedded within real-world care settings, thereby accelerating the pace and relevance of post-market evidence generation.
By combining their complementary strengths, Paradigm Health and Flatiron Health aim to rebuild the U.S. clinical research ecosystem so it is more inclusive, more efficient and better aligned with national priorities to modernize trial delivery. Their shared goal is clear: create a research infrastructure that reflects real-world populations, reduces barriers for providers, expands trial access into community settings and ultimately brings new therapies to patients faster. Terms of the transaction were not disclosed.
